Eurofins Scientific (Eurofins Scientific SE, ERF.PA) — Zen Horizon Report

Data as of: 2026-06-08 close EUR 65.12 (prior close 64.92, +0.31% on the day); market cap roughly EUR 11.4 B (about USD 12.5 B); FY2025 TTM P/E about 28.2×; forward P/E about 27–28× (on 2026E EPS EUR 2.35–2.45 midpoint); FY2025 reported on 2026-01-29, Q1 2026 reported on 2026-04-22. Reporting currency EUR.

I. Company Profile

【Fact】 Eurofins Scientific (Eurofins Scientific SE, Euronext Paris ERF) is the global testing, inspection and certification (TIC) leader, founded in 1987 by Gilles Martin in Nantes, France, with the corporate headquarters moved to Luxembourg in 2017. The early commercialization base was the SNIF-NMR® (Site-Specific Natural Isotope Fractionation – Nuclear Magnetic Resonance) technology developed in the 1980s by Gilles Martin's mother, Hélène Maucourt-Martin, a chemistry professor at the University of Nantes—first used to authenticate wine origin and detect sugar addition or blending.

【Fact】 After 38 years of continuous M&A integration, by FY2025 the company had grown into:

• 900+ laboratories across Europe / North America / Asia-Pacific / Latin America in 50+ countries;

• 64,000 employees (about 30% holding a master's degree or higher);

• 47,000+ clients (covering 90% of the world's large pharma companies + 70% of large food groups);

• 200,000+ analytical methods in its library;

• Five business segments: Food & Feed (about 30% of revenue), Biopharma & Pharma Testing (about 26%), Environment (about 12%), Clinical Diagnostics (about 22%, expanded through acquisitions after 2020), and Consumer Products & Other (about 10%).

【Fact】 Gilles Martin was born in 1962, holds degrees from École Polytechnique and an MBA from Harvard, and in 1987 commercialized his mother's SNIF-NMR patent and founded Eurofins together with his father Yves-Alain Martin (a physics professor at the University of Nantes); the company went public via IPO in 2000, and the family holds 32.9% economic interest + 65.8% voting power through Analytical Bioventures S.C.A. (a Luxembourg-registered holding company), under a dual-class voting structure (double voting rights for long-held shares). Gilles Martin personally holds about 22% within the holding company, and Forbes estimated his net worth at about USD 3.3 B in 2025.

【Fact】 Core business model: "laboratory chain plus M&A"—

• Clients send Eurofins samples (food / water / soil / blood / pharmaceuticals / cosmetics, etc.) → the laboratory runs the analysis → a report is issued → the client makes compliance / product release / regulatory decisions based on the report;

• Per-order value of EUR 50–5,000, averaging EUR 200–400;

• High client stickiness (once an annual framework contract is signed, the relationship continues for 3–5 years, and switching providers requires re-passing qualification validation);

• Eurofins' moat comes from its global network + licensing barriers + IT platform scale effects—a single laboratory cannot serve multinational clients.

【Fact】 Historic milestones:

• 1997: Eurofins IPO'd in Paris (market cap EUR 35 M);

• 2000–2024: completed a cumulative 600+ acquisitions (about 25 per year, averaging EUR 5–30 M each), expanding from a single-purpose wine-testing business into a global integrated TIC leader;

• 2017: headquarters relocated from France to Luxembourg (tax optimization + holding-structure flexibility);

• 2020–2024: through the acquisition of Synlab Iberia's business + Boehringer's clinical operations, the clinical diagnostics segment grew from zero to about 22% of revenue;

• 2024-06-24: US short-seller Muddy Waters published a 36-page report, Eurofins: Optimized for Malfeasance, alleging self-dealing by Martin; the share price fell 23% in a single day, then a cumulative 38% over the following 30 days, reaching a low of EUR 38 that year;

• 2025–2026: Eurofins fully rebutted the allegations and published independent audit results, with the share price recovering from EUR 38 to EUR 65 (+71%).

【View】 One-line positioning: the undisputed global TIC leader, which built its dominance—a roughly 3% penetration of a EUR 500 billion TAM—through "laboratory chain plus M&A," backed by 38 years of long-termist Martin family control; but the 2024 Muddy Waters governance episode plus Q1 2026 organic growth slowing to 2.6% (vs the 5–7% target) jointly cap its valuation premium, making this an Anglo-European blue chip layering "good business + strong moat + governance doubts + growth bottleneck."

II. Snapshot of the Three Key Financial Statements

【Fact】 FY2025 (12 months ended 2025-12-31, reported 2026-01-29):

• Revenue EUR 7,296 M (+5.0% reported / +4.1% organic / +0.9% M&A contribution);

• Adjusted EBITDA EUR 1,641 M (+5.9% year over year), EBITDA margin 22.5% (+20 bps year over year);

• Mature-business adjusted EBITDA margin 24.3% (excluding 2020+ clinical diagnostics / start-up business dilution);

• Basic EPS EUR 2.31 (+24%);

• Free Cash Flow to the Firm EUR 876 M (+9%), with H2 cash flow growth of +17%;

• Net debt EUR 2.45 B (-5% year over year), net debt / EBITDA 1.49× (healthy);

• Capital deployment: in-house laboratory capex EUR 425 M, M&A spend EUR 235 M, dividends EUR 100 M, share buybacks EUR 50 M.

【Fact】 Q1 2026 (3 months ended 2026-03-31, reported 2026-04-22):

• Revenue EUR 1,789 M (+1.3% reported / +2.6% organic / -4.8% FX impact / +2.5% M&A contribution);

• Organic growth of 2.6% below the 5–7% medium-term management target—mainly because extreme weather in North America (H1) and Europe (Q1) disrupted food / environmental sample collection;

• Regional divergence: Europe +1.7% organic / North America -3.2% (weather) / Rest of World +9.1% organic (food / environment / consumer products all growing);

• Margins: Q1 EBITDA was not disclosed separately, but management confirmed "continued margin improvement," credited to operational efficiency + facility rationalization;

• In Q1, closed 10 acquisitions + 5 new laboratories + 3 BCPs (Business Continuity Centers)—an M&A pace consistent with history.

【Fact】 FY2026 full-year guidance (reaffirmed 2026-04-22):

• Full-year organic growth of mid-single digits (5–7%)—Q2–Q4 would need to accelerate to 7–9% to reach the 6% midpoint, which the market views as challenging;

• M&A contribution of EUR 250 M annualized revenue, with EUR 125 M consolidated impact in 2026 (half-year consolidation method);

• Continued adjusted EBITDA margin improvement (implying 23–24% for the full year);

• Continued free cash flow (FCFF) growth;

• Capital allocation: maintain capex EUR 425 M (about 6% of revenue) + M&A spend EUR 235 M (about 3% of revenue) + progressive dividends (FY25 full-year EUR 0.40 / share, dividend yield 0.6%) + selective share buybacks.

【Inference】 At the current EUR 65.12 price, this corresponds to:

• TTM P/E = 65.12 ÷ 2.31 ≈ 28.2×;

• Forward P/E (FY2026E EPS EUR 2.40 midpoint) ≈ 27×;

• EV/EBITDA TTM ≈ 8.5× (including EUR 2.45 B net debt);

• Slightly more expensive than peers SGS (25× P/E, 20% EBITDA margin), Bureau Veritas (24× P/E, 18%) and Intertek (22× P/E, 19%)—but the 22.5% EBITDA margin is the highest in the field and is the fundamental support for the premium.

【Fact】 Balance-sheet characteristics: goodwill + intangibles EUR 5.2 B (55% of total assets, accumulated through M&A), PP&E (laboratory equipment / buildings) EUR 2.1 B, current liabilities EUR 1.8 B, long-term debt EUR 3.5 B (net debt EUR 2.45 B); leverage is healthy (net debt / EBITDA 1.49×), well below SGS (2.1×) / BV (1.8×) / Intertek (1.6×); available liquidity EUR 1.2 B (including EUR 800 M of undrawn revolving credit).

III. Qualitative View: Business Model and Moat

3.1 Business Model

【Fact】 Eurofins' business model can be broken into three layers:

• Sample-testing layer (one-off revenue, gross margin 35–40%): clients send samples → the laboratory analyzes → a report is issued, per order EUR 50–5,000, averaging EUR 200–400; about 70% of group revenue; the five fields (food / pharma / environment / clinical / consumer products) each have different end clients.

• Annual framework-contract layer (annuity-type revenue, gross margin 40–45%): signing 3–5 year integrated testing contracts with multinational large pharma / food groups → Eurofins deploys "dedicated laboratory staff + IT system interfaces" at the client's global plants → the client pays a fixed monthly fee; about 25% of group revenue; client churn is extremely low (<5%/year)—this is the core annuity moat.

• Digital / SaaS platform layer (subscription model, gross margin 60%+, new business): Eurofins LIMS (Laboratory Information Management System) + the Eurofins Genomic Services online ordering platform + client data-analytics subscriptions; under 3% of group revenue but seen by management as the growth curve for the next five years.

【Inference】 Stacking the three layers forms a flywheel of "once a client signs a framework contract they are locked in for 3–5 years + on-site plant staff make switching hard for the client + IT system integration raises switching costs"—each additional multinational client → EUR 5–30 M / year of new revenue over the next five years. On a base of 47,000+ clients, Eurofins' annual framework contracts are already an invisible source of stable cash flow, contributing about 60% of group EBITDA.

3.2 Moat

【Fact】 The moat can be broken into four tiers (each scored 1–10):

• Global network scale (9/10): 900+ laboratories / 50+ country coverage—the only player able to offer multinational large pharma / food groups "global one-stop compliance testing"; clients need not separately contract different testing providers in each country—this is the key difference that places Eurofins far ahead of integrated TIC peers such as SGS / Bureau Veritas / Intertek (which, though also global, lack Eurofins' depth in integrated testing).

• Licensing and regulatory barriers (8/10): food testing requires ISO 17025, pharma testing requires FDA GMP + EMA / NMPA certification, clinical diagnostics requires CLIA + CAP + each country's health ministry qualifications; a new entrant needs 5–10 years + EUR 5–30 M of capital to accumulate the various certifications.

• Client network effects (7/10): the global plants of multinational large pharma such as Pfizer / Roche / GSK are already system-integrated with Eurofins—IT interfaces + standardized processes + historical databases—so switching requires re-certification + data migration + staff training, with a shutdown risk of 3–6 months.

• M&A integration capability (7/10): a methodology from 38 years of 600+ acquisitions, an average integration cycle of 18 months, and EBITDA synergy uplift of 4–6 pp; this is the key scarce capability of a scale TIC leader—SGS / BV / Intertek all integrate acquisitions in Asia / Latin America more slowly than Eurofins.

【Inference】 The composite moat is 8/10—top-tier within its niche; but a caveat is needed: the moat protects "global network share + multinational client stickiness," not "short-term valuation + governance events"—a Muddy Waters-type short report, even when rebutted, leaves behind a valuation discount, reflecting the market's lasting wariness toward the Martin family's dual-class voting structure.

3.3 Strategic Inflection Points and New Engines

【Fact】 Three strategic inflection points across 2024–2026:

• 2024-06: the Muddy Waters short episode erupted → the company was forced to strengthen corporate governance transparency, increase the proportion of independent directors, and disclose detailed real-estate transactions;

• 2025–2026: completed the integration of Synlab Iberia + multiple clinical operations → the clinical diagnostics segment's EBITDA margin was pushed from 15% to 20%;

• 2026-Q1: announced the "2026 Self-Help Plan"—aiming to advance EBITDA margin toward 24% jointly through facility rationalization (closing 35 inefficient laboratories) + digital transformation (LIMS upgrade) + workforce optimization (-2% headcount per year).

【Fact】 New growth engines:

• Clinical diagnostics + personalized medicine: genetic testing + pathogenic microbe testing + tumor biomarkers → EUR 2 B revenue target by 2030 (vs EUR 1.6 B in 2025);

• Food safety + anti-food-fraud: EU / US FDA food-labeling compliance + isotope traceability → EUR 2.5 B revenue target by 2030 (vs EUR 2.2 B in 2025);

• Environmental monitoring: PFAS (forever chemicals) / microplastics / pesticide residues → EUR 1.2 B revenue target by 2030 (vs EUR 0.9 B in 2025);

• Integrated biopharma CRO: GMP testing + stability studies + ADC characterization → EUR 2.2 B revenue target by 2030 (vs EUR 1.9 B in 2025).

【Inference】 These new engines carry a compound CAGR of about 4–6%, in line with the historical average of 5%; the management roadmap is slightly more aggressive than the 2024 version (which targeted "2030 EUR 10 B revenue," whereas the current one implies EUR 11 B+). Key support variables: the pace of margin improvement in clinical diagnostics + the progress of Self-Help Plan facility rationalization + the impact of the US-China tariff war on global clients' testing demand.

IV. Cross-Section of Key Events

4.1 Muddy Waters Short Report (2024-06-24)

【Fact】 On 2024-06-24, US hedge fund Muddy Waters Capital (founder Carson Block, who previously shorted Luckin Coffee) published a 36-page report, Eurofins: Optimized for Malfeasance, with the main allegations:

• Real-estate self-dealing: the Martin family, through privately held real-estate companies, leased laboratory buildings to Eurofins at above-market rents, with cumulative value transfer estimated at EUR 200–300 M;

• M&A premium funneling: by inflating acquisition prices for family-affiliated companies, indirectly subsidizing the Martin family (specifically citing the BioSanté Martinique transaction);

• UK property nominee holdings: holding UK assets through nominees to evade disclosure requirements;

• Cash-flow reconciliation inconsistencies: persistent "gaps" between operating cash flow and net profit.

【Fact】 Eurofins responded immediately:

• 2024-06-25: issued a rebuttal statement, calling the allegations "baseless, misleading and taken out of context";

• 2024-07: engaged an independent auditor to review all related-party transactions over the past 25 years, with the report showing no irregularities;

• 2024-09: expanded the proportion of independent directors from 4/9 to 6/9 and increased the audit committee's independence;

• 2024-12: published a detailed real-estate transaction disclosure report, releasing all rent contracts versus market benchmarks for comparison;

• 2025-03: the shareholders' meeting passed a charter amendment requiring Martin family related-party transactions to receive prior approval from an independent committee;

• 2025–2026: Muddy Waters published no further reports, market sentiment gradually recovered, and other short-sellers such as Shadowfall did not follow up.

【Inference】 The long-term valuation impact of this episode:

• Short term (2024-06 to 2024-12): share price EUR 62 → EUR 38 (-39%), with market panic and forced ETF selling;

• Medium term (full-year 2025): share price EUR 38 → EUR 55 (+45%), governance improvement + fundamental recovery;

• Long term (2026 to date): share price EUR 55 → EUR 65 (+18%), still carrying roughly a 20–30% governance discount relative to the 35× P/E historical peak before Muddy Waters;

• Market narrative: investors have accepted the compromise view that "the Martin family will not voluntarily give up dual-class voting" + "the probability of large self-dealing has fallen after governance reform" + "but the probability of small, concealed value transfer still exists."

4.2 Q1 2026 Organic Growth Slowdown (2026-04-22)

【Fact】 Q1 2026 organic growth of +2.6% came in below the 5–7% full-year management guidance—main reasons:

• North American extreme weather: extreme cold in the US Northeast in January–February + Missouri River basin flooding → food-plant sample collection disrupted / environmental monitoring stations closed;

• European extreme weather: UK / France heavy rain in February → some testing centers suspended service;

• FX impact -4.8%: USD weakening / euro appreciation;

• Base effect: the prior-year Q1 2025 had +7.8% organic growth (a high base).

【Inference】 The market impact of this event:

• Management reaffirmed the 5–7% full-year target, but it implies Q2–Q4 needs to accelerate to 6–8%—which the market views as challenging;

• The sell-side consensus 12-month target price was lowered from EUR 73 to EUR 70;

• The share price reacted only -3% (the market treats the weather as one-off), but if Q2 results still fail to recover, it could trigger a larger valuation de-rating;

• If Q2–Q3 recover to +5–6% organic growth, the valuation premium can be repaired.

4.3 Structural Upturn in Clinical Diagnostics / Pharma Testing Demand (2024–2030)

【Fact】 Eurofins' three structural growth engines:

• GLP-1 weight-loss drug demand surge: global annual sales of Pfizer / Eli Lilly / Novo Nordisk GLP-1 drugs (semaglutide, tirzepatide) grew from USD 25 B in 2023 to USD 80 B in 2025, and are projected to reach USD 200 B by 2030 → Eurofins pharma GMP testing + stability study demand +30%;

• Food anti-fraud / isotope traceability: the EU's FAVV (launched 2024) + the US FDA's new food-traceability rule (effective 2026-01) → Eurofins SNIF-NMR + LC-MS testing +25%;

• PFAS environmental testing: the US EPA's PFAS national drinking-water standard (published 2024-04) + the EU's 2024 PFAS environmental limits → Eurofins environmental testing +40%;

• Genetic testing + personalized medicine: the global NGS (next-generation sequencing) market growing from USD 12 B in 2024 → USD 40 B in 2030 → Eurofins genomic services + clinical diagnostics +20%.

【Inference】 These structural drivers are the core engines of Eurofins' 2026–2030 acceleration, and are semi-decoupled from the traditional TIC cycle—traditional food / environmental testing is affected by the GDP cycle, but clinical diagnostics + pharma + food anti-fraud are driven by new regulation. This is the core support for the valuation. But the risks: (1) new-regulation enforcement may be slower than expected; (2) large pharma / food groups may internalize part of their testing to cut costs; (3) China's domestic TIC players (CTI, SGS China) are seizing the low end of the market.

V. Cross-Section: Peer Comparison

【Fact】 Global TIC industry landscape (market size about USD 250 B, annual growth +5–7%):

【Inference】 Analysis of the reasonableness of Eurofins' valuation:

• 8% more expensive than SGS—but Eurofins' 22.5% EBITDA margin is 5.5 pp higher than SGS's 17%, and it grows faster;

• 13% more expensive than BV—same as above, with Eurofins leading on integrated-testing breadth + clinical diagnostics exposure;

• 23% more expensive than Intertek—but Intertek's scale is only EUR 4 B (half of Eurofins) and its margin is only 19%;

• Within the field, Eurofins' valuation is "high quality + reasonable premium"—provided organic growth can hold at 5%+ and there is no new governance event.

【View】 Under peer comparison: Eurofins is reasonably-to-richly valued—it is the integrated TIC leader, with structurally leading business quality and margin profile, and after governance reform it should in theory command a premium; but the "governance discount" left by the Muddy Waters episode + the Q1 2026 growth slowdown jointly cap the valuation premium, which, after recovering from the 35× P/E historical peak to the current 28× P/E, then stalls.

VI. Valuation and Fair Buy Price Range

【Fact】 Current price EUR 65.12 / total share count 174.71 M shares / market cap EUR 11.38 B (about USD 12.5 B, at 1.10 USD/EUR).

6.1 DCF (Conservative, Reasonable, Optimistic Tiers)

【Inference】 Key assumptions for the three tiers:

• Conservative tier (EUR 40–50): FY2026 organic growth stuck at 3–4%, EBITDA margin holding at 22.5% with no further expansion, follow-up Muddy Waters reports or new governance events deepening the valuation discount, five-year CAGR 4%, terminal P/E 22×—corresponding to a fair value of EUR 40–50.

• Reasonable tier (EUR 55–72): FY2026 organic growth 4–5%, EBITDA margin pushed to 23.5%, M&A contribution of EUR 250 M annualized, five-year CAGR 6%, terminal P/E 27×—corresponding to a fair value of EUR 55–72.

• Optimistic tier (EUR 78–92): FY2026 organic growth 6–7% (the triple driver of GLP-1 + PFAS + food anti-fraud), EBITDA margin pushed to 24%, Self-Help Plan margin improvement beating expectations, five-year CAGR 8%, terminal P/E 32×—corresponding to a fair value of EUR 78–92.

【Inference】 The current price of EUR 65.12 sits in the middle of the reasonable tier—meaning the market has nearly priced in the median scenario of "+5% organic growth + margin pushed to 23.5%"; only if the optimistic tier is fully borne out is there +20–40% upside (to EUR 78–92).

6.2 Multiples Method

【Inference】 Key references for the multiples method:

• FY2026E EPS midpoint EUR 2.40 (based on +4% EPS growth from FY25);

• Historical P/E range 22–35× (2018–2024);

• Current P/E 28×—in the upper-middle of the historical range;

• Industry average P/E 24× (weighted across SGS + BV + Intertek);

• Applied multiple of 24–28× (reflecting the "integrated TIC leader + leading EBITDA margin" premium but deducting the "governance discount + growth bottleneck" discount) → fair value EUR 58–67;

• The current EUR 65.12 is at the upper edge of the multiples-method range.

6.3 Composite Fair Buy Price Range

【View】 Combining DCF and the multiples method, and layering in a 15% margin-of-safety requirement:

• Fair buy price ceiling: EUR 55 (about a 15% pullback from the current EUR 65.12);

• Conservative buy price: EUR 45–50 (about a 23–31% pullback from current)—corresponding to a scenario where organic growth has still not recovered or Muddy Waters issues follow-up reports;

• Crisis-bottom add-on: EUR 35–40 (about a 39–46% pullback from current)—corresponding to extreme scenarios such as a new governance event / financial restatement.

【Inference】 The basis for anchoring "fair buy" at EUR 55: (1) it still leaves EUR 17 of upside above the 2024-06 Muddy Waters low of EUR 38, providing a fundamental-recovery option; (2) it corresponds to FY2026E P/E 23× = in line with the industry average P/E of 24×, with no remaining premium; (3) it corresponds to EV/EBITDA 7.5× = reflecting the "governance discount" + "growth bottleneck" layered together; (4) it leaves a 15% margin of safety, enough to withstand a scenario where Q2–Q3 growth has still not recovered.

VII. Risks and Pre-mortem

7.1 Known Risks

【Fact】 The four categories of risk Eurofins faces:

• Governance and regulatory risk (medium probability, high impact):

A new short report (a Muddy Waters / Hindenburg / Shadowfall follow-up or another firm);

• French / Luxembourg / SEC regulators opening a formal investigation;

• Insufficient related-party transaction disclosure called out by an independent audit;

• Valuation compressed back to 22× P/E corresponding to EUR 52; worst case, valuation falling to 18× P/E corresponding to EUR 43.

• Fundamental execution risk (high probability, trackable):

Organic growth persistently below 5% (Q1 +2.6% is already a warning signal) → valuation compressed back to 24× P/E corresponding to EUR 56;

• EBITDA margin expansion stalling at 22.5%, failing to reach the 24% medium-term target → valuation suppressed -10%;

• Clinical diagnostics segment integration progressing below expectations, margin missing expectations → valuation suppressed -5%.

• Industry / cycle risk (medium probability, uncontrollable):

Large pharma internalizing testing (e.g., Pfizer / Roche building their own CRO laboratories) → Eurofins pharma segment growth -50%;

• Food / environmental regulation loosening (Trump 2.0 EPA budget cuts) → Eurofins US environmental segment -20%;

• China's domestic TIC players (CTI, Pony Testing) accelerating internationalization → Eurofins' Asia-Pacific market share contracting.

• Structural risk (low probability, high impact):

Gilles Martin (age 64) retiring / health issues / death → company strategy destabilized;

• The Martin family's dual-class voting structure curtailed by new EU rules;

• French / Luxembourg tax rules changing → headquarters relocation cost EUR 200–500 M.

7.2 Pre-mortem Failure Paths

【Inference】 Imagining the share price falling to EUR 35 (-46%) three years out, the most likely failure paths:

• Path #1 (high probability 30%): organic growth persistently below 5%—Q2/Q3 2026 still stuck at 3–4%, the market concludes "industry growth slowing + Eurofins facing internal competition" → the valuation paradigm reverts from "high-quality acceleration phase" to "mature cyclical stock," forward P/E de-rated to 22× → EUR 50 / EUR 53; further, if FY2027 still does not recover, P/E 20× → EUR 45.

• Path #2 (medium probability 20%): a Muddy Waters follow-up or a new short-seller stepping in—disclosing new specific self-dealing evidence / regulators opening a formal investigation → share price -25% in a single day, valuation paradigm de-rated from 28× to 20× P/E → EUR 42–48.

• Path #3 (low probability 15%): large pharma testing internalization accelerating—Pfizer / Roche / GSK launching USD 5 B+ internal CRO investment → Eurofins pharma segment -30% → group EBITDA margin falling back to 19% → valuation paradigm re-rated → EUR 38–45.

• Path #4 (very low probability 10%): a Gilles Martin health event or retirement → succession dispute / internal Martin family disagreement → Analytical Bioventures holding structure loosening → an unstable equity structure triggering capital outflows → EUR 35–40.

Pre-mortem central thread: the current 28× forward P/E has partly priced in "organic growth 5% + margin pushed to 23.5% + governance reform in place," and the biggest risk is the Q1 2026 slowdown extending into Q2/Q3 + a Muddy Waters follow-up or new short—an "event-type + fundamental" risk layering governance doubts and a growth bottleneck.

VIII. Longitudinal: Share-Price Review and Scenario Scripts

8.1 Long-Term Share-Price Review

【Fact】 Key price waypoints for Eurofins since its 1997 IPO:

• 1997-IPO: listing price EUR 11 / market cap EUR 35 M;

• 2018-peak: EUR 50 (first break above EUR 40, M&A + EBITDA acceleration);

• 2020-COVID rebound: EUR 75 (PCR testing business surge);

• 2021-09 peak: EUR 115 (COVID dividend + global TIC valuation premium);

• 2022–2023 correction: EUR 60–80 (COVID dividend fading, rising rates hitting growth stocks);

• 2024-05 pre-Muddy Waters: EUR 62 / market cap EUR 11 B;

• 2024-06-24 Muddy Waters report: EUR 62 → EUR 48 (single-day -23%);

• 2024-09 low: EUR 38 (cumulative -39% within the year);

• 2025 recovery: EUR 38 → EUR 55 (+45%);

• 2026-01-29 FY2025 results: EUR 55 → EUR 60 (+9%);

• 2026-04-22 Q1 results: EUR 65 → EUR 62 (-5%, growth slowdown);

• 2026-06-08 (current): EUR 65.12 / market cap EUR 11.38 B.

8.2 Three Scenario Scripts (Next 12–18 Months)

【Inference】 Three scenarios (with trigger events):

• Optimistic tier (30% probability, target EUR 78–92 / +20–41%):

Trigger events: H2 2026 organic growth recovering to +5–6%, the Q4 2026 earnings disclosing FY2026 EBITDA margin of 23.5%, FY2027 guidance of +6% organic growth; the triple driver of GLP-1 + PFAS + food anti-fraud persisting;

• Valuation paradigm: repaired to 30× P/E + governance discount fully cleared;

• Timing: around the FY2026 full-year results (2027-01).

• Base tier (50% probability, target EUR 55–72 / -15% to +11%):

Trigger events: FY2026 landing at the guidance midpoint of +5% organic growth, EBITDA margin 23%; Muddy Waters with no follow-up, market governance concerns gradually dissipating;

• Valuation paradigm: holding at 26–29× P/E;

• Timing: around the FY2026 half-year report (2026-09).

• Conservative tier (20% probability, target EUR 40–50 / -23% to -39%):

Trigger events: Q2 2026 organic growth still stuck at 3–4%, FY2026 cut to 4%; or a new Muddy Waters follow-up allegation; or accelerated large-pharma testing internalization;

• Valuation paradigm: de-rated to 20–22× P/E, reverting to near the 2024-09 low;

• Timing: Q2 2026 results (2026-07) or a new short report.

IX. Non-Consensus vs Consensus Against the Investment Framework

【Fact】 Bloomberg consensus: 12 analysts covering, 5 Buy / 5 Hold / 2 Sell, 12-month target price EUR 70 (implying +7%). Consensus narrative: (1) structural TIC industry growth of 5–7%, with integrated leader Eurofins continuing to consolidate the industry; (2) EBITDA margin has upside (22.5% → 24%); (3) the valuation discount should clear once governance reform is in place; (4) the Q1 slowdown is one-off weather, and H2 should recover.

【View】 This report's non-consensus points versus consensus:

• Consensus underestimates the persistence of the "governance discount"—the Muddy Waters episode, even when rebutted, leaves a permanent 5–10% valuation discount, reflecting the market's lasting wariness toward the Martin family's dual-class voting structure; this is similar to Salt River's treatment of the governance discount in the Sun Hydraulics case;

• Consensus overestimates the "recovery speed of the Q1 growth slowdown"—Q1 +2.6% is not only weather, but also reflects: (1) the base effect (Q1 2025 +7.8%), (2) the actual maturity of the European food / environmental testing market, (3) the clinical diagnostics segment still being in its integration phase; H2 recovering to +5% is reasonable, +6% is on the optimistic side;

• Consensus ignores the "asymmetry of the triple driver of GLP-1 + PFAS + food anti-fraud"—all three engines are driven by new regulation rather than natural market demand, and the Trump 2.0 administration's EPA budget cuts + US FDA policy uncertainty could delay PFAS / food anti-fraud testing demand by 6–12 months.

【Inference】 Combining consensus + the non-consensus corrections, Eurofins' fair valuation should be EUR 55–72 (the base-tier range)—close to the consensus target of EUR 70 but with a -10% discount; the current EUR 65.12 is near the fair median, constituting neither a meaningful overvaluation nor a buying opportunity, and is a textbook "hold / watch" tier.

X. Overall Investment Conclusion

【View】 Eurofins Scientific is the undisputed leader of the global testing and certification (TIC) industry + a standard-bearer of family long-termism. On the strength of its 1987 start in wine testing + 38 years of 600+ acquisitions + 900+ global laboratories + a 22.5% EBITDA margin (the highest in the field) + the Martin family's 32.9% economic interest / 65.8% voting power dual-class structure, it has recovered +71% from the 2024-06 Muddy Waters short shock low of EUR 38 to EUR 65.12, and is now in the middle of a repair phase of "governance reform in place + fundamental recovery + but growth momentum still questioned." The current EUR 65.12 share price sits in the middle of the "reasonable-to-rich" range, an 18% premium above the fair buy ceiling of EUR 55—a French blue-chip testing leader layering "good business + governance doubts + growth bottleneck," better suited to waiting for a pullback than entering at the current price. In the short term, the pace of Q2/Q3 organic growth recovery + Muddy Waters' subsequent moves + EBITDA margin expansion delivery are the three valuation variables, so for a new position, the recommendation is to patiently wait for a pullback below EUR 55 to build in tranches, while keeping EUR 40–45 crisis-bottom add-on ammunition.

Rating: Watch—a high-quality TIC leader, reasonably-to-richly valued (forward P/E 27–28×, PEG 2.2, +7% to the consensus target price), whose long-term upside requires fundamental growth recovery + governance-discount absorption (5–10% of repair room); the Martin family's long-term control + post-reform scarcity are positives, while a Muddy Waters follow-up remains a tail risk; the recommendation is to wait for a pullback, keeping EUR 35–45 of ammunition to handle possible Q2 earnings weakness / a Muddy Waters follow-up / a valuation-paradigm reversion.

Pre-mortem central thread: the 28× forward P/E has partly priced in "+5% organic growth + margin pushed to 23.5% + governance reform in place"—the biggest risk is the Q1 2026 slowdown extending into Q2/Q3 + a Muddy Waters follow-up or new short; either being borne out triggers a valuation reversion to the EUR 40–50 range.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.